132 related articles for article (PubMed ID: 38451491)
21. Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Olson R; Jiang W; Liu M; Bergman A; Schellenberg D; Mou B; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Chng N; Matthews Q; Baker S; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresene S; Tyldesley S
JAMA Oncol; 2022 Nov; 8(11):1644-1650. PubMed ID: 36173619
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary function and quality of life after VMAT-based stereotactic ablative radiotherapy for early stage inoperable NSCLC: a prospective study.
Ferrero C; Badellino S; Filippi AR; Focaraccio L; Giaj Levra M; Levis M; Moretto F; Torchio R; Ricardi U; Novello S
Lung Cancer; 2015 Sep; 89(3):350-6. PubMed ID: 26164208
[TBL] [Abstract][Full Text] [Related]
23. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy.
Ayoub Z; Ning MS; Brooks ED; Kang J; Welsh JW; Chen A; Gandhi S; Heymach JV; Vaporciyan AA; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):261-269. PubMed ID: 32044413
[TBL] [Abstract][Full Text] [Related]
24. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
[TBL] [Abstract][Full Text] [Related]
25. Post-treatment survival difference between lobectomy and stereotactic ablative radiotherapy in stage I non-small cell lung cancer in England.
Khakwani A; Harden S; Beckett P; Baldwin D; Navani N; West D; Hubbard R
Thorax; 2020 Mar; 75(3):237-243. PubMed ID: 31879316
[TBL] [Abstract][Full Text] [Related]
26. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.
Chang JY; Lin SH; Dong W; Liao Z; Gandhi SJ; Gay CM; Zhang J; Chun SG; Elamin YY; Fossella FV; Blumenschein G; Cascone T; Le X; Pozadzides JV; Tsao A; Verma V; Welsh JW; Chen AB; Altan M; Mehran RJ; Vaporciyan AA; Swisher SG; Balter PA; Fujimoto J; Wistuba II; Feng L; Lee JJ; Heymach JV
Lancet; 2023 Sep; 402(10405):871-881. PubMed ID: 37478883
[TBL] [Abstract][Full Text] [Related]
27. Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.
Tekatli H; van 't Hof S; Nossent EJ; Dahele M; Verbakel WFAR; Slotman BJ; Senan S
J Thorac Oncol; 2017 Jun; 12(6):974-982. PubMed ID: 28286243
[TBL] [Abstract][Full Text] [Related]
28. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in medically inoperable early stage lung cancer patients treated with stereotactic ablative radiation therapy (SABR): Turkish Radiation Oncology Society Multicentric Study.
Sahin B; Atalar B; Kaytan Saglam E; Akgun Z; Abacioglu U; Arifoglu A; Ozyar E; Yaprak G; Ozseker Isik N; Guney Y; Caglar HB; Karaman S; Igdem S; Selek U; Berber T; Oner Dincbas F; Sengoz M; Yucel S; Demiral AN; Akyurek S
Clin Respir J; 2020 Nov; 14(11):1050-1059. PubMed ID: 32749053
[TBL] [Abstract][Full Text] [Related]
30. Stereotactic Ablative Body Radiotherapy Versus Radical Radiotherapy: Comparing Real-World Outcomes in Stage I Lung Cancer.
Phillips I; Sandhu S; Lüchtenborg M; Harden S
Clin Oncol (R Coll Radiol); 2019 Oct; 31(10):681-687. PubMed ID: 31377081
[TBL] [Abstract][Full Text] [Related]
31. Long-term quality of life in early-stage non-small cell lung cancer patients treated with robotic stereotactic ablative radiation therapy.
Mathieu D; Campeau MP; Bahig H; Larrivée S; Vu T; Lambert L; Lavoie C; Roberge D; Doucet R; Carrier JF; Gorgos A; Fortin B; Filion E
Pract Radiat Oncol; 2015; 5(4):e365-73. PubMed ID: 25680997
[TBL] [Abstract][Full Text] [Related]
32. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.
Liu H; Zhang X; Vinogradskiy YY; Swisher SG; Komaki R; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):1017-23. PubMed ID: 22543216
[TBL] [Abstract][Full Text] [Related]
33. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
[TBL] [Abstract][Full Text] [Related]
34. Lung volume reduction after stereotactic ablative radiation therapy of lung tumors: potential application to emphysema.
Binkley MS; Shrager JB; Leung AN; Popat R; Trakul N; Atwood TF; Chaudhuri A; Maxim PG; Diehn M; Loo BW
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):216-23. PubMed ID: 25015205
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.
Boily G; Filion É; Rakovich G; Kopek N; Tremblay L; Samson B; Goulet S; Roy I;
J Thorac Oncol; 2015 Jun; 10(6):872-82. PubMed ID: 26001140
[TBL] [Abstract][Full Text] [Related]
36. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms.
Kang J; Ning MS; Feng H; Li H; Bahig H; Brooks ED; Welsh JW; Ye R; Miao H; Chang JY
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):90-99. PubMed ID: 31586665
[TBL] [Abstract][Full Text] [Related]
37. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
[TBL] [Abstract][Full Text] [Related]
38. Correlation of biologically effective dose and the tumor control in Stage I (<5 cm) non-small cell lung cancer with stereotactic ablative radiotherapy: a single institutional cohort study.
Jeon W; Ahn SJ; Kim YC; Oh IJ; Park CK; Jeong JU; Yoon MS; Song JY; Nam TK; Chung WK
Jpn J Clin Oncol; 2018 Feb; 48(2):144-152. PubMed ID: 29194510
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer.
Haasbeek CJ; Lagerwaard FJ; Slotman BJ; Senan S
J Thorac Oncol; 2011 Dec; 6(12):2036-43. PubMed ID: 21892102
[TBL] [Abstract][Full Text] [Related]
40. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
